Infliximab chimeric antitumor necrosis factor-α monoclonal antibody as potential treatment for myelodysplastic syndromes

REFERENCES

• Hellstrom-Lindberg E, Willman C, Barrett AJ, Saunthararajah Y. Achievements in understanding and treatment of myelo-dysplastic syndromes. Hematology (Am Soc Hematol Educ Prog) 2000;110— 132.
   Google Scholar
• Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Prog) 2003;176–199.
   Google Scholar
• Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol 2003;33:153–160.
   Google Scholar
• Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett 1991;285:199–212.
   Google Scholar
• Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, Rifkin S, Iftikhar A, Shetty V, Parcharidou A. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268–276.
   Google Scholar
• Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996;20: 891–900.
   Google Scholar
• Mundle SD, Mativi BY, Bagai K, Feldman G, Cheema P, Gautam U, Reza S, Cartlidge JD, Venugopal P, Shetty V, etal. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. Int J Hematol 1999;70: 83–90.
   Google Scholar
• Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P, Gregory SA, Raza A. Correlation of tumor necrosis factor alpha (TNF alpha) with high caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999;140:201–207.
   Google Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates im-mune effector functions. Cytokine 1995;7: 251–259.
   Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337: 1029–1035.
   Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594–1602.
   Google Scholar
• Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359: 1187–1193.
   Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of inffiximab mono-therapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842–1847.
   Google Scholar
• Reimold AM. New indications for treatment of chronic inflammation by TNF-alpha blockade. Am J Med Sci 2003;325:75–92.
   Google Scholar
• Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bc1-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96:3932–3938.
   Google Scholar
• Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Mor-phological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granu-locyte-C SF and erythropoietin. Leuk Res 1997;21:415–425.
   Google Scholar
• Tsoplou P, Kouraklis-Symeonidis A, Thanopoulou E, Zikos P, Orphanos V, Zoumbos NC. Apoptosis in patients with myelodysplastic syndromes: differential involvement of mar-row cells in 'good' versus 'poor' prognosis patients and correlation with apoptosis-related genes. Leukemia 1999;13:1554–1563.
   Google Scholar
• Parker JE, Fishlock KL,, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. 'Low-risk' myelodysplastic syndrome is asso-ciated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bc1-2-related proteins. Br J Haematol 1998;103:1075–1082.
   Google Scholar
• Ali A, Mundle SD, Ragasa D, Reza S, Shetty V, Mativi BY, Cartlidge JD, Azharuddin M, Qawi H, Dar S, Raza A. Sequential activation of caspase-1 and caspase-3-like proteases during apoptosis in myelodysplastic syndromes. J Hematother Stem Cell Res 1999;8: 343–356.
   Google Scholar
• Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998;91:1235–1242.
   Google Scholar
• Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34 + human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183–3190.
   Google Scholar
• Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88: 6961–6965.
   Google Scholar
• De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E, Riccioni R, Felli N, Samoggia P, Peschle C. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999;93:796–803.
   Google Scholar
• Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, Okamura T, Gondo H, Niho Y. Functional expression of Fas antigen (CD95) on hematopoietic progeni-tor cells. Blood 1995;86: 883–889.
   Google Scholar
• Gersuk GM, Lee JW, Beckham CA, Anderson J, Deeg HJ. Fas (CD95) receptor and Fas-ligand expression in bone marrow cells from patients with myelodysplastic syndrome. Blood 1996;88: 1122–1123.
   Google Scholar
• Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leuke-mia 1998;12:486–492.
   Google Scholar
• Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, MelleJ, Lacombe C, Gisselbrecht S, Mayeux P, Dreyfus F. Ineffective erythropoiesis in myelodysplastic syndromes: cor-relation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 1999;106:464–473.
   Google Scholar
• Gupta P, Niehans GA, LeRoy SC, Gupta K, Morrison VA, Schultz C, Knapp DJ, Kratzke RA. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival. Leukemia 1999;13:44–53.
   Google Scholar
• Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodys-plastic syndromes. Leukemia 1997;11: 839–845.
   Google Scholar
• Rajapaksa R, Ginzton N, Ron LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;88:4275–4287.
   Google Scholar
• Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, Troutt AB, Ledbetter JA, Deeg HJ. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176–188.
   Google Scholar
• Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11:2049–2054.
   Google Scholar
• Peddie CM, Wolf CR, McLellan U, Collins AR, Bowen DT. Oxidative DNA damage in CD34 + myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997;99: 625–631.
   Google Scholar
• Sawanobori M, Yamaguchi S, Hasegawa M, Inoue M, SuzukiK, Kamiyama R, Hirokawa K, Kitagawa M. Expression of TNF receptors and related signalling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003;27:583–591.
   Google Scholar
• Pruneri G, Bertolini F, Soligo D, Carboni N, Cortelezzi A, Ferrucci PF, Buffa R, Lambertenghi-Deliliers G, Pezzella F. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81:1398–1401.
   Google Scholar
• Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leuke-mia progenitor formation in myelodysplastic syndromes. Blood 2001;97:1427–1434.
   Google Scholar
• Stasi R, Amadori S. The role of angiogenesis in hematologic malignancies. J Hematother Stem Cell Res 2002;11:49–68.
   Google Scholar
• Arimura K, Arima N, Matsushita K, Ohtsubo H, Fujiwara H, Kukita T, Ozaki A, Hagiwara T, Hamada H, Yoshino K, TeiC. Matrix metalloproteinase inhibitor reduces apoptosis induction of bone marrow cells in MDS-RA. Eur J Haematol 2004;73:17–24.
   Google Scholar
• Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH, Drummond AH, Galloway WA, Gilbert R, Gordon JL. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994;370:555–557.
   Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JI,, Wolfson MF, Casmer BJ, Stocking KL, Reddy P, Srinivasan S, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385:729–733.
   Google Scholar
• Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777–1783.
   Google Scholar
• Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 2000;95:1580–1587.
   Google Scholar
• Nemunaitis J, Rosenfeld C, Getty L, Boegel F, Meyer W, Jennings LW, Zeigler Z, Shadduck R. Pentoxifylline and ciprofloxacin in patients with myelodysplastic syndrome. A phase II trial. Am J Chin Oncol 1995;18:189–193.
   Google Scholar
• Klausner JD, Freedman VH, Kaplan G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Chin Immunol Immunopathol 1996;81:219–223.
   Google Scholar
• Raza A, Meyer P, Dun D, Zorat F, Lisak L, Nascimben F, du Randt M, Kaspar C, Goldberg C, Loew J, Dar S, Gezer S, Venugopal P, Zeldis J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98:958–965.
   Google Scholar
• Zorat F, Shetty V, Dun D, Lisak L, Nascimben F, Allampallam K, Dar S, York A, Gezer S, Venugopal P, Raza A. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001;115:881–894.
   Google Scholar
• Maciejewski JP, Risitano AM, Sloand EM, Wisch L, Geller N, Barrett JA, Young NS, Ristiano AM. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 2002;117:119–126.
   Google Scholar
• Deeg HJ, Gotlib J, Beckham C, Dugan K, Holmberg L, Schubert M, Appelbaum F, Greenberg P. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 2002;16:162–164.
   Google Scholar
• Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol 2001;13:164–169.
   Google Scholar
• Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003;102:2768–2776.
   Google Scholar
• Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004;104:649–654.
   Google Scholar
• Raza A, Candoni A, Khan U, Lisak L, Tahir S, Silvestri F, Billmeier J, Alvi MI, Mumtaz M, Gezer S, et al. Remicade as TNF suppressor in patients with myelodysplastic syndromes. L,euk Lymphoma 2004;45:2099–2104.
   Google Scholar
• Stasi R, Brunetti M, Bussa S, Conforti M, Martin LS, La Presa M, Bianchi M, Parma A, Pagano A. Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syn-drome. Chin Lab Haematol 1997;19:197–201.
   Google Scholar